TY - JOUR
T1 - Richter transformation in the era of novel agents
AU - Ding, Wei
N1 - Funding Information:
Conflict-of-interest disclosure: W.D. is on the advisory board for Merck and Alexion and has received research funding from Merck.
Funding Information:
The author thanks Jennifer Brown, Sameer Parikh, Nitin Jain, and Neil E. Kay, who provided critical review of this paper, and Rong He and Timothy Call, who provided important input. W.D. received support from National Cancer Institute grant K23 CA160345; Mayo Clinic Cancer Center/Richard M. Schulze Family Foundation for Awards in Cancer Research; and the Fraternal Order of Eagles Cancer Research Fund.
Publisher Copyright:
© 2018 American Society of Hematology. All rights reserved.
PY - 2018/11/30
Y1 - 2018/11/30
N2 - Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.
AB - Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.
UR - http://www.scopus.com/inward/record.url?scp=85058770743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058770743&partnerID=8YFLogxK
U2 - 10.1182/asheducation-2018.1.256
DO - 10.1182/asheducation-2018.1.256
M3 - Article
C2 - 30504319
AN - SCOPUS:85058770743
SN - 1520-4391
VL - 2018
SP - 256
EP - 263
JO - Hematology (United States)
JF - Hematology (United States)
IS - 1
ER -